Immuneering to bolster cancer pipeline, expand services unit with $17M series A

Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline. Some of the $17 million from the untranched series A round, led by Boxcar PMJ and supported by undisclosed family offices and individuals, will go to expand the company’s computational biology services business.

Co-founder and CEO Ben Zeskind told BioCentury that revenues from that business, in which it analyzes patients’ gene expression changes to better understand drugs’ mechanisms of action, had allowed the company to avoid raising venture money since its founding in 2008. ...